Recent data have underlined a possible role of G D3 synthase (GD3S) and complex gangliosides in Estrogen Receptor (ER) negative breast cancer progression. Here, we describe the main transcript of the GD3S coding gene ST8SIA1 expressed in breast tumors. We characterized the corresponding core promoter in Hs578T breast cancer cells and showed that estradiol decreases ST8SIA1 mRNA expression in ER-positive MCF-7 cells and ERa-transfected ER-negative Hs578T cells. The activity of the core promoter sequence of ST8SIA1 is also repressed by estradiol. The core promoter of ST8SIA1 contains two putative Estrogen Response Elements (ERE) that were not found to be involved in the promoter activity pathway. However, NFkB was shown to be involved in ST8SIA1 transcriptional activation and we demonstrated that estradiol prevents NFkB to bind to ST8SIA1 core promoter in ERa expressing breast cancer cells by inhibiting p65 and p50 nucleus localization. The activation of NFkB pathway in ER-negative tumors, due to the absence of estradiol signaling, might explain the overexpression of G D3 synthase in this tumor subtype.
Introduction
Gangliosides are glycosphingolipids carrying one or several sialic acid residues, and are essential compounds of the plasma membrane, by exposing their glycan moiety to the extracellular domain. They are enriched together with other phospholipids and cholesterol in lipid microdomains named ''glycosynapses'', where they can modulate cell signaling, leading to changes in cellular phenotype [1, 2] . Glycosphingolipids from ganglio-series represent the main class of gangliosides and are usually classified in four series according to the presence of 0 to 3 sialic acid residues linked to lactosylceramide [3, 4] .
While normal tissues usually express 0-and a-series gangliosides, gangliosides from b-and c-series are mostly expressed during embryogenesis and in the central nervous system in healthy adults, where they play a key role in cell-cell interaction, differentiation and growth [5, 6] . In parallel, complex gangliosides such as G D3 , G T3 or G D2 have been found over-expressed in human tumors of neuroectoderm origin such as melanoma, glioblastoma and neuroblastoma [7] [8] [9] . They play a functional role in tumor growth and metastasis by mediating cell proliferation, migration, adhesion and angiogenesis [10] . Complex gangliosides have also been used as target molecules for cancer immunotherapy, such as G D3 in melanoma [11, 12] and G D2 in neuroblastoma [13, 14] .
In normal breast tissues, complex gangliosides are absent or expressed at very low level. However G D3 , 9-O-acetyl-G D3 and 9-O-acetyl-G T3 are oncofetal markers in invasive ductal breast carcinoma (IDC) [15] . Clinical studies have also shown that high expression of ST8SIA1, the gene coding the G D3 synthase (GD3S), is associated with Estrogen Receptor (ER) negativity and high histological grade of breast tumors [16, 17] . The GD3S is the only a2,8-sialyltransferase that synthesizes the disialoganglioside G D3 from its precursor G M3 [18, 19] . GD3S is therefore the key enzyme controlling the biosynthesis of complex gangliosides from b-and cseries.
In order to determine the role of complex gangliosides in breast cancer progression, we have previously induced GD3S overexpression in ER-negative MDA-MB-231 breast cancer cell line [20] . The resulting cellular model, MDA-MB-231 GD3S+, displayed a proliferative phenotype in absence of exogenous growth factor. This proliferative capacity of MDA-MB-231 GD3S+ clones directly proceeded from the constitutive activation of c-Met Tyrosine Kinase Receptor [21] and we recently showed that the ligand-independent activation of c-Met was due to the expression of G D2 ganglioside at the cell surface of GD3S+ clones [22] . Altogether, these data strongly suggest a possible role of GD3S and complex gangliosides in ER-negative breast cancer progression. Moreover, high G D2 expression was recently detected in breast cancer stem cells that was shown to be critical for mammosphere formation and tumor initiation [23] . Notably, GD3S but not G M2 /G D2 synthase correlated with G D2 expression and GD3S knockdown reduced cancer stem cells properties and tumor formation.
To elucidate the molecular mechanisms leading to overexpression of GD3S in breast cancer, we have undertaken the study of the transcriptional regulation of the GD3S coding gene, ST8SIA1, in breast cancer cells. ST8SIA1 is located on chromosome 12, in p12.1-p11.2 locus and consists in five coding exons spanning over 135 kbp [24] . Several reports have described the 59-untranslated region (59-UTR) of ST8SIA1 in melanoma [24, 25] , glioblastoma [26] and neuroblastoma [27] cell lines, showing a unique transcript with transcription start sites (TSS) located 400 to 650 bp upstream the initiation codon on the first exon. In this study, we described the main ST8SIA1 transcript expressed in breast cancer tumors and cell lines and we characterized the core promoter of this gene. We also showed that estradiol repressed endogenous ST8SIA1 mRNA expression as well as ST8SIA1 core promoter activity by preventing NFkB binding in two human breast cancer cell lines expressing Estrogen Receptor alpha (ERa). 
Materials and Methods

Breast Cancer Tumor Collection
Cell Culture
The human breast cancer cell line Hs578T [28] was kindly provided by Dr Van Slambrouck (New Mexico Institute of Mining and Technology, NM, USA). The human breast cancer cell line MCF-7 was obtained by the ATCC (Rockville, MD, USA). Both cell lines were routinely grown in Dulbecco's Modified Eagle Medium (DMEM) with 4.5 g/L glucose, Ultraglutamine 1 supplemented with 10% fetal calf serum and 100 mg/mL penicillin-streptomycin (Lonza, Verviers, Belgium), at 37uC in an atmosphere of 5% CO 2 . When necessary, cells were grown for 48h in DMEM without phenol-red containing 10% charcoal-stripped serum (Invitrogen, Carlsbad, CA, USA) before treatment 24 or 12 h with 17-b-estradiol (Sigma Aldrich, Lyon, France) and/or Tamoxifen (TAM) (Sigma) and/or Tumor Necrosis Factor (TNF) (AbCys, Paris, France) or ethanol as vehicle.
59-Rapid Amplification of cDNA Ends (59-RACE)
The 59-RACE system for Rapid Amplification of cDNA ends (Invitrogen) was used according to the protocol provided by the manufacturer. Initial reverse transcription was performed with the RT primer (annealing to the ST8SIA1 sequence) using 4 mg of total RNA. After synthesis of the first strand cDNA, nested PCR was performed using PlatinumH Taq DNA polymerase (Invitrogen). GSP1/Anchor primer and GSP2/AUAP primer pairs were used for first and second PCR, respectively. PCR products were sizeseparated by Agarose gel electrophoresis, subcloned into pCR2.1-TOPO vector (Invitrogen) and sequenced by Genoscreen (Lille, France).
Plasmids Construction and Mutagenesis
ESR1 open reading frame was amplified from MCF-7 cells cDNA with the primer pair ERaNhe1 and ERaKpn1 (Table 1) . The PCR product was digested by Nhe1 and Kpn1 and cloned into the pcDNA3.1 expression vector (Invitrogen). The resulting plasmid was designed pcDNA-ERa. pCMV-p50 and pCMV-p65 vectors, expressing p50 and p65 NFkB subunits respectively, were previously described [29] .
Genomic DNA of Hs578T cells was prepared with Nucleospin Extract II kit (Macherey-Nagel, Düren, Germany) following manufacturer's instructions. The genomic sequence located between 22307 bp and the ATG site was amplified by PCR using the primer pair P1Nhe1 and P2Xho1 ( Table 1 ). The PCR product was cloned into the pCR2.1-TOPO vector (Invitrogen). The promoter sequence was then isolated by digestion of the vector using Nhe1 and Xho1 restriction sites. The purified fragment was sub-cloned into pGL3-Enhancer vector (Promega, Madison, USA) upstream of the firefly luciferase gene at Nhe1/ Xho1 sites. The resulting plasmid was designed pGL3(22307/+1). Truncated promoter constructs were generated by enzymatic digestions, ends blunting and ligation ( Table 2 ). All plasmid constructs were sequenced to ensure the absence of mutation (Genoscreen, Lille, France).
Mutations with base substitutions at Estrogen Response Element (ERE) binding sites on pGL3(2923/2565) were obtained using a Quick Change mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol, using the oligonucleotide primers shown in Table 1 . The plasmid mutations were verified by sequence analysis.
RNA Extraction, cDNA Synthesis and Quantitative PCR
Total RNA from tumor samples or breast cancer cells was extracted using the Nucleospin RNA II (Macherey-Nagel). RNA quality was checked using the Agilent Bioanalyser 2100 (Agilent technologies, Santa Clara, CA, USA). Total RNA was reverse transcribed using Affinity script qPCR cDNA Synthesis kit (Agilent) according to the protocol provided by the manufacturer.
Primer sequences (Eurogentec, Seraing, Belgium) used for the PCR reactions are given in Table 1 . Quantitative real-time Polymerase Chain Reaction (qPCR) was performed using the Mx3005p Quantitative System (Stratagene) as previously described [20] . Briefly, 40 cycles were performed according to the following program (94uC for 30 s, 60uC for 30 s, and extension at 726C for 30 s).The analysis of amplification was performed using the Mx3005p software. For each primer pair, the specificity of the amplification was checked by recording the dissociation curves, visualizing the amplified products in Agarose-gel electrophoresis and sequencing of the products. HPRT or RPLP0 genes were used to normalize the expression of transcripts of interest. Relative quantification was performed using the method described by Pfaffl, that takes in account the efficiency of each sequence amplification [30] .
Bioinformatic Analysis
In silico analysis of the promoter was performed with BLAST analysis of the human genome of the NCBI database. Multiple sequence alignments were performed with the Multalin program (http://multalin.toulouse.inra.fr/multalin/multalin.html).
The core promoter sequence was analyzed with Matinspector 8.0 (www.genomatix.de) using TRANSAC matrices 8.4 [31] with ''core similarity: 0.950 and ''matrice similarity : optimized''.
Transient Transfection and Luciferase Assay
Hs578T cells (80% confluency) were transfected using lipofectamine (Invitrogen) according to the manufacturer's instructions, with 1.5 mg of pGL3 construction and 20 ng of control Renilla plasmid in UltraMEM medium (Invitrogen). When necessary, 2 mg of pcDNA-ERa and 1 mg of pCMV-p50 and pCMV-p65 expression vectors were added to the transfection mix. After 6 h, the medium was replaced by fresh culture medium containing 10% FCS and further incubated for 48h. Cells were then washed with Phosphate Buffered Saline (PBS), lysed with Passive Lysis Buffer (PLB, Dual Luciferase Reporter Assay System, Promega, Madison, USA) and 20 mL of lysate were used for luciferase Reporter Assay System. Luminescence was measured with the Centro luminometer (Berthold Technologies, Bad Wildbad, Germany).
Nuclear Protein Extraction and Western Blotting Analysis
ERa expressing Hs578T and MCF-7 cells transfected or not with pCMV-p50 and pCMV-p65 were lysed on ice in a hypotonic buffer (Hepes 10 mM, MgCl 2 1.5 mM, KCl 10 mM, pH 7.9) supplemented with 0.125% NP40 and protease cocktail inhibitors (Roche, Meylan, France). The lysate was centrifuged 5 min at 10,000 g. The pellet corresponding to the nuclear fraction was lysed with hypertonic buffer (Hepes 20 mM, MgCl 2 1.5 mM, EDTA 0.2 mM, NaCl 0.5 M, glycerol 25%, pH 7.9) supplemented with protease cocktail inhibitors on ice during 2 h. The protein concentration was determined with the Micro BCA TM Protein Assay Reagent kit (Pierce, Rockford, IL, USA). 40 mg of total proteins were boiled for 10 min in reducing Laemmli sample buffer and resolved by SDS-PAGE on 8% or 12% mini-gels (BioRad, Richmond, USA). After transfer onto a nitrocellulose membrane (80 mA overnight), blocking was performed using Tris Buffer Saline (TBS) containing 0.05% Tween 20 and 5% (w/v) non-fat dried milk for 1 h at room temperature (RT). Incubations Table 1 . Primers used for 59-RACE, qPCR and plasmid constructions. 
59-CTCTCATCTTAGGCTTTGTATTTTG-39
ChIP-NFkB forward 3
59-AGAACAAGGGCACGAGTGAG-39
ChIP-NFkB reverse 3
59-AGAAAAGAACTCGCTCTCATCAGT-39
P1Nhe1 forward 3
59-CTCCCTGCTAGCTTTGCAGAAGAAAGAAAAACAGC-39
P2Xho1 reverse 3
59-CAAATTCTCGAGCCCTCTGGACGTTTGTCG-39
ERaNhe1 forward Provided by Invitrogen. 3 Designed using the NCBI primer design software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). 4 Designed using the QuickChange primer design software (http://labtools.stratagene.com/QC). Restriction site sequences inserted for cloning are underlined and the mutated nucleotides in primers used for site directed mutagenesis are in bold. doi:10.1371/journal.pone.0062559.t001
with anti-p65 (sc-7151x), anti-p50 (sc-1190x) mAbs (Santa Cruz Biotechnology Inc., Europe) and anti-histone H2B (07-371) mAb (Millipore, Billerica, USA) were performed 1 h at RT in TBS, 0.05% Tween 20 and 5% (w/v) non-fat dried milk. After washing, membranes were incubated 1 h at RT in TBS, 0.05% Tween 20 and 5% (w/v) non-fat dried milk of horseradish peroxydase conjugated to anti-mouse, anti-goat or anti-rabbit IgG. Membranes were finally washed 3 times for 10 min in TBS, 0.05% Tween 20 and detection was achieved using enhanced chemiluminescence (ECL+H advanceWestern blotting detection reagents, Amersham Biosciences, Little Chalfont, Buks, U.K.).
Chromatin Immunoprecipitation (ChIP)
Hs578T-ERa and MCF-7 cells (1610 6 cells per antibody) were treated with 1% (v/v) formaldehyde for 10 min at room temperature and cross-links were quenched with glycine at a final concentration of 0.125 M for 5 min. Cells were rapidly rinsed with ice-cold D-PBS (Dulbecco-PBS) containing a cocktail of protease inhibitors (Roche), and scraped off and collected by centrifugation at 700 g for 5 min at 4uC, before being resuspended in lysis buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 and 0.1% Nonidet P40) plus protease inhibitors and incubated for 10 min on ice. Chromatin was sheared with the Bioruptor system (Diagenode). The extracts were sonicated for 10 pulses of 30 s each with a 30 s rest between each pulse at 200 W at 4uC. After clearing by centrifugation at 10,000 g for 10 min at 4uC, the supernatant was fractionated and precipitated with either 3 mg of the specific antibody or normal goat IgGs (Upstate Biotechnology). An aliquot of the total supernatant was removed as input control. Immunoprecipitation was performed overnight on a rotating platform at 4uC, a mixture of Protein G and Protein A magnetic beads (Invitrogen) was then added and left for another 3 h as previously described [32] . Magnetic beads were collected and washed sequentially in Low Salt Immune Complex wash buffer (5 times), High Salt buffer (Upstate) and TE buffer [10 mM Tris/HCl (pH 8.0) and 1 mM EDTA]. The complexes were eluted with 210 ml of elution buffer [0.05 M Tris/HCl (pH 8.0), 0.01 M EDTA and 1% SDS] after a 15 min incubation at 65uC. Formaldehyde cross-links were reversed with 0.2 M NaCl at 65uC overnight. Chromatin-associated proteins were digested with Proteinase K at 37uC for 1 h and the DNA was purified with the WizardH DNA Clean-up System (Promega). Samples were then subjected to qPCR analysis as described previously using ChIPNFkB primers pair ( Table 1) . Percentage of input was determined using the Pfaffl method [30] and normalized to the IgG control which was set to 1. (Fig. 1A) . The sequencing of the resulting products indicated that ST8SIA1 transcription also started within E1 exon, giving raise to T1 transcripts with different TSS between 2345 and 220 bp upstream the ATG. Two minor transcripts (named T2 and T3) with alternative 59-ends were also detected and located 34 and 150 kbp upstream E2 exon, respectively (Fig. 1B) . The expression of T1 transcript was analyzed in 20 ER-negative IDC samples by qPCR and related to total ST8SIA1 expression. As shown in Fig. 1C , the total expression of ST8SIA1 was higher in tumor samples compared to Hs578T cells and T1 accounted for 50 to 100% of the total transcripts, making it the main ST8SIA1 transcript across this series of tumor samples.
Results
Identification of
Human GD3S Transcripts in Breast Cancer Cells The 59-UTR of ST8SIA1 transcripts was analyzed in Hs578T cell line (expressing ST8SIA1 at higher level than others tested breast cancer cell lines) and 20 tumor samples of ER-negative IDC. The 59-UTR of ST8SIA1 transcripts were previously reported in melanoma, glioblastoma and neuroblastoma cell lines, showing a unique transcript, called T1, with several TSS within the first exon E1, from 2400 to 2650 bp upstream the ATG [24-27]. 59-UTR amplification was performed for Hs578T cells and 3 tumor samples representative of the different levels of ST8SIA1 expression (#137, #142 and #144) by 59-RACE as described in the Material and Methods section
Promoter Activity of the 59-flanking Region Upstream the GD3S T1 Transcript
To determine the core promoter sequence of the T1 transcript, the genomic sequence located between 22307 bp and the ATG site in E1 was cloned into the pGL3basic upstream the luciferase gene and named pGL3(22307/+1). This plasmid and the 5'-or 39-deleted constructs, were transfected into Hs578T cells for luciferase assays. The results presented in Fig. 2 showed a 2.9-fold increase of luciferase activity for the full length plasmid pGL3(22307/+1) compared to pGL3basic used as baseline control. By comparison, all constructs lacking the 2565/+1 region showed increased activities with maximal promoter activities for pGL3(21117/2565) and pGL3(2923/2565) constructs (7.4-and 7.0-fold, respectively). In parallel, 59 truncations of various length induced decreased luciferase activity with pGL3(2565/+1) and pGL3(2335/+1) constructs showing almost no activity compared to pGL3basic (1.2-and 1.5-fold, respectively). Together, these data suggest the existence of a core promoter region of GD3S within the sequence 2923/2565 and a negative regulation region within 2565/+1.
Bioinformatics' Analysis of T1 Core Promoter Region
The putative core promoter sequence 2923/2565 was analyzed with Matinspector software with ''core similarity: 0.950 and ''matrice similarity: optimized''. This analysis did not reveal any canonical TATA or CAAT boxes as previously reported by others [24] . However, a large number of putative binding sites for general (e.g. SP1) and specific transcription factors were retrieved. Positions of putative transcription factors related to breast cancer are presented in Table 3 . Notably, two putative Estrogen 
Estradiol Represses Endogenous ST8SIA1 Transcripts in ER-positive MCF-7 and in ER-negative ERa-transfected Hs578T Cells
Given that ST8SIA1 is over-expressed in ER-negative breast tumors [16] and that its core promoter contains two putative sites for ERa binding, we investigated the effect of estradiol on ST8SIA1 mRNA expression in breast cancer cell lines MCF-7 and Hs578T. for 24h. PS2/TFF1 (Trefoil Factor 1) gene, known to be upregulated by estradiol [33] was similarly analyzed to control the estradiol responsiveness of the treated cells. As shown in Fig. 3A , estradiol expectedly increased PS2 expression while ST8SIA1 expression decreased significantly (about 4.5 fold). TAM treatment abolished the increased PS2 expression but has no antagonistic effect on estradiol-mediated GD3S mRNA repression. Similar experiment was performed in ER-negative Hs578T cells transfected or not with the pcDNA-ERa vector 24h before estradiol treatment. Estradiol had no significant effect on the expression of PS2 or ST8SIA1 in mock-transfected Hs578T cells (Fig. 3B) . In contrast, in Hs578T exogenously over-expressing ERa, estradiol induced an increase of PS2 expression as well as a slight but significant decrease of ST8SIA1 expression. Taken together, our results demonstrate that estradiol represses ST8SIA1 expression in an ERa dependent manner.
The Core Promoter Activity is Inhibited by Estradiol through an ERE-independent Manner Involving NFkB Transcription Factor
To demonstrate the role of EREs found in the core promoter in the estradiol-mediated ST8SIA1 regulation, we analyzed the activity of the promoter sequence 2923/2565 in estradiol treated Hs578T cells transfected or not with pcDNA-ERa. As shown in Fig. 4A , estradiol had no significant effect on the core promoter activity in mock-transfected Hs578T cells (control). In parallel, ERa expression allowed a significant decrease of the luciferase activity (50%) in estradiol treated cells. A similar fold of repression was obtained for the pGL3(21117/2565) construct (data not shown). However, site-directed mutagenesis of either one or both putative ERE on pGL3(2923/2565) construct did not suppress the repressive action of estradiol (Fig. 4A) . This result suggests that the ERE sites are not involved in ER signaling and that estradiol exerts an indirect effect on the ST8SIA1 promoter activity. Lee and coworkers described a functional NFkB binding site on ST8SIA1 promoter in melanoma cells [25, 27] that we also confirmed by bioinformatic analysis at position 2777/2762 (Table 3) . As shown in Fig. 4A , the mutation of NFkB binding site led to a significant decrease of luciferase activity (30%), demonstrating NFkB to be involved in ST8SIA1 promoter activity in breast cancer cells. Notably, directed mutagenesis of others predicted transcription factors binding sites described in Table 3 have no effect on the activity of the core promoter (data not shown). Moreover, p50 and p65 expression vectors transfection or TNF treatment, both inducing an increase of p50 and p65 NFkB subunits in the nucleus (Fig. 4B) , resulted in a 2-fold increase of luciferase activity (Fig. 4A) . Furthermore, we showed that estradiol inhibited the NFkB-mediated increase of ST8SIA1 promoter activity in Hs578T-ERa cells (Fig. 4A ). This could be explained by the inhibitory effect of estradiol on p50 and p65 nuclear localization (Fig. 4B) . Altogether, these data show the role of NFkB in transcriptional activation of ST8SIA1 promoter in breast cancer cells and suggest that estradiol inhibits NFkB-mediated activation by preventing p50 and p65 NFkB subunits translocation into the nucleus.
Estradiol Decreased Endogenous NFkB Binding to ST8SIA1 Promoter in ERa-Expressing Breast Cancer Cell Lines
To confirm that NFkB directly acts on ST8SIA1 promoter, ChIP experiments were performed using Hs578T expressing ERa and MCF-7 cells treated with TNF, in absence or in presence of estradiol (Fig. 5) . We found that the region 2868/2665 of the ST8SIA1 promoter, encompassing the 2777/2762 NFkB binding site, was enriched for p65 over the negative control IgG both in Hs578T-ERa and MCF-7 cell lines, showing that p65 directly binds this promoter region in these cells. Estradiol treatment led to a significant decrease of p65 binding in both Hs578T-ERa and MCF-7 cell lines. As shown in Fig. 6 , the loss of NFkB binding on ST8SIA1 promoter is associated with a decrease of endogenous ST8SIA1 mRNA expression in both MCF-7 and Hs578T-ERa cells. Furthermore, confirming the results obtained with the corepromoter constructs, TNF treatment of MCF-7 and Hs578T-ERa cells led to a 2.9-and 2.4-fold increase of ST8SIA1 mRNA expression, respectively, and estradiol treatment reverted this effect.
Discussion
In this paper, we determined that T1 is the major transcript of GD3S expressed in breast tumor tissues and we characterized the core promoter essential for transcription of GD3S in human breast cancer cells. In breast tumor tissues, the 59-UTR of T1 transcript is shorter but similar to the one found in other cell lines [24] [25] [26] [27] . Furthermore, we newly described minor transcripts as T2 and T3 with alternative first exon that lack initiation codon. Similar aberrant non-coding transcripts have recently been described in tumors and have been suggested to play functional roles in cancer progression and metastasis [34] . Interestingly, the core promoter we identified in breast cancer cells, between 2923 and 2565 upstream the initiation codon, overlaps with the core promoter found in melanoma (2833/2519) [24] and neuroblastoma (21190/2690) [27] but not with the one found in glioblastoma (21330/21190) [26] , suggesting a tissue-specific regulation of ST8SIA1. In the present study, we show an ERa-mediated estradiol downregulation of both endogenous GD3S mRNA and core promoter activity in breast cancer cells. This result fits well with a microarray analysis showing an inverse correlation between ST8SIA1 and ESR1 (coding ERa receptor) gene expression in invasive breast cancer primary tumors [16, 17] . We therefore propose that high expression of GD3S in ER-negative tumors, due to the loss of ERa signaling, could increase complex gangliosides expression at the cell surface, and through this possibly enhance the aggressiveness of this tumor subtype [21, 23] .
Transcriptional regulation by steroid hormones has been showed for several sialyltransferases. For instance, ST3Gal III and ST6Gal I were demonstrated to be up-regulated and downregulated respectively by estradiol in MCF-7 breast cancer cells [35] . Testosterone was also shown to up-regulate ST3Gal II expression, through epigenetic regulation involving NFkB, in prostate cancer cells [36] .
TAM is an estradiol antagonist used to treat ER-positive breast cancer patients. It plays an active role in inhibition of breast cancer cells proliferation through repression of ERa responsive genes normally involved in cell proliferation [37] . Although TAM treatment of Hs578T cells efficiently prevented the expression of PS2, a well characterized estradiol responsive gene, it did not compete with estradiol-induced ST8SIA1 repression. Reassuringly, our results suggest that TAM treatment of breast cancer patients is unlikely to induce the expression of possibly deleterious complex gangliosides via ST8SIA1 induction in ER-positive breast cancer tumors.
Although bioinformatics analysis indicate two ERE on the core promoter, site mutagenesis of these predicted EREs in Hs578T cells failed to confirm their cis-regulatory function in ST8SIA1 transcription. However, it was reported that estradiol-mediated down-regulation of gene expression can be classified in two groups according to the kinetic of their response to the hormone [38, 39] . Early-down-regulated genes are often primary targets of estrogen receptor, while late-down-regulated genes require secondary factors for transcription [38] . In our cells, ST8SIA1 downregulation was only observed after 8h of estradiol treatment (data not shown) suggesting ST8SIA1 to be indirectly regulated by estradiol (i.e. without direct binding of ERa to ST8SIA1 promoter).
A functional NFkB binding site at 2777/2762 pb upstream the ATG was shown to be essential for ST8SIA1 transcription in melanoma cells [25, 27] . NFkB is a transcription factor frequently activated in tumors that is involved in tumor growth, progression and resistance to chemotherapy [40] . In particular, activated NFkB is predominantly detected in ER-negative vs. ER-positive breast tumors [41, 42] . Accordingly, several studies have shown that ERa can inhibit NFkB activity in an estradiol-dependent manner in various cell lines [43] . For example, estradiol was shown to prevent p65 activation and to inhibit its intracellular transport to the nucleus via the activation of PI3K. This effect is mediated by ERa and selectively activated in macrophages to prevent the inflammatory response [44] . It was also shown that estradiol inhibits TNF-induced NFkB activation in MCF-7 cells [45] . Here, we show that NFkB is involved in transcriptional activation of GD3S in both Hs578T-ERa and MCF-7 breast cancer cells and that estradiol represses GD3S expression by inhibiting p65 and p50 nucleus transport (Fig. 7) . This could explain the higher expression of GD3S in ER-negative breast cancer cells and tumors, in which the effect of NFkB cannot be repressed by estradiol, leading to a higher amount of complex gangliosides that reinforce proliferative capacity of the tumor. Delineating the molecular mechanisms by which estradiol represses GD3S in breast cancer cells could provide new targets to inhibit complex gangliosides synthesis and potentially hamper ER-negative breast tumors aggressiveness. Potential therapeutic strategy targeting NFkB would prevent complex gangliosides expression in ER-negative breast tumors. Drugs that inhibit NFkB signaling have been identified and are currently undergoing clinical trials in combination with standard anti-tumor agents to achieve a better treatment of tumors and an increase in survival [46] .
